The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
about
Successes and Challenges of PARP Inhibitors in Cancer TherapyHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionThe role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapyFemtosecond near-infrared laser microirradiation reveals a crucial role for PARP signaling on factor assemblies at DNA damage sites.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsTwo decades after BRCA: setting paradigms in personalized cancer care and preventionPoly (ADP-ribose) polymerase inhibitors: recent advances and future development.PARP1 Inhibitors: antitumor drug design.Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.A BRCA1-interacting lncRNA regulates homologous recombination.E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetA phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocEvaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.Genomic Biomarkers for Breast Cancer Risk.PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving TargetsThe unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.Reverse the Resistance to PARP Inhibitors.Refining the role of BRCA1 in combating oxidative stress.Development of anticancer drugs based on the hallmarks of tumor cells.Phosphoproteomic approach to characterize protein mono- and poly(ADP-ribosyl)ation sites from cells.Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.Embracing synthetic lethality of novel anticancer therapies.Advances in PARP inhibitors for the treatment of breast cancer.Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.New therapeutic perspectives in CCDC6 deficient lung cancer cells.A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.Stalled replication forks within heterochromatin require ATRX for protection.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
P2860
Q26777131-E3D5E4E8-0EFB-4A43-8247-A8149F7F0E0FQ26783551-F835DE1B-B4E3-4D0E-8F3E-A34A74C7A874Q26851765-C28DB150-761F-45A2-A384-52A2A2B24B9BQ27010084-C0617206-E1C1-4484-B6A6-764D732D8E33Q27324256-BB7FC2E0-C4E1-4308-B42E-FE7E47E280BFQ28071345-FA6B43FB-881F-4A86-AF1D-7D2027FC6AF9Q33820594-9C43FDB5-8226-490A-9ABB-5330B8FBA5BFQ35895214-F3C5F166-1EAF-4908-BAF0-A0D8EFACFE96Q36175159-14E961A1-6768-4164-8302-AF06D9C49AAFQ36235684-E536CDBB-1CFE-4441-AA45-C821FAEBD26CQ36270867-8B4BB5C1-A240-4BAB-9044-00FD2D143EA1Q36562360-42902F66-91F3-41E0-A7E2-A0EF85661AD7Q36990060-051C8605-FF5A-47FA-8000-34B1ED672826Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8Q37158437-AB6B7ED3-F5A4-4A90-9D4B-896AF958655BQ37173597-3102C883-2196-4D9C-8DD5-E2A28CA5FA3AQ37242239-02697F9A-327A-47DF-84FA-16D1553ECD2DQ37307055-A54DEB37-CE0E-462F-BDDD-BC4D6C252000Q37385372-F928C59D-5D39-420A-B557-B7CD4ED2466AQ37605747-E3ACAF7E-D8D1-486A-9938-3A3697EAC6E8Q37675896-86B01A73-F34C-4FF0-9D08-0E6A927EABD6Q37689775-B0B86B23-62CF-4A8A-81F1-645996A266F2Q38182491-9C817B70-EB6D-42C3-9978-5D04EBD3847BQ38306460-E76AAA52-F93B-499B-B31A-8FC8296D928FQ38433579-FA32E1C1-F5B1-453E-96EF-028B9785FF63Q38554530-62B9396A-CB54-407C-8F6F-B3961B0049F4Q38612128-99D51DEE-B802-4952-A1D4-B5FB440A3CA0Q38718686-C90C1259-A85D-4EBB-A4C8-C4B20014D452Q38817669-A31D9FE9-36AB-4748-BFF3-89C2BE511DC8Q38949133-BD102CF8-DE88-4DD6-A707-04BA5E1AD7DAQ39510346-B5699FBD-DA37-49C7-8427-CF513E2C7CE0Q41369694-43702179-2414-4B40-B3F5-550F9E21BFB1Q41924768-3EB3E8B6-6F1D-4410-95EF-A0651F8F12DFQ42459032-394A5A1F-A80B-473A-A845-D02FE2388DDCQ47761787-B1C9D237-D5F9-4BE3-9A44-E1AD473C1059Q48110433-B91DCEF8-00D6-4731-B824-11ED3D3D810FQ49852384-7822FD8C-9430-4F16-B840-001E976B1728Q50098388-AFAD0553-422B-4EDD-89ED-E606A487DD93Q52764412-90E2F8BA-E0B0-4A98-A958-94B41C94B6D8Q52773665-46C3ECD5-BA10-4940-B651-E550D8155FE1
P2860
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The Elephant and the Blind Men ...... ination Deficient Tumor Cells.
@en
type
label
The Elephant and the Blind Men ...... ination Deficient Tumor Cells.
@en
prefLabel
The Elephant and the Blind Men ...... ination Deficient Tumor Cells.
@en
P2860
P356
P1476
The Elephant and the Blind Men ...... bination Deficient Tumor Cells
@en
P2093
Rachel M Hurley
Silvana B De Lorenzo
P2860
P356
10.3389/FONC.2013.00228
P577
2013-09-11T00:00:00Z